PAVmed Inc. (PAVM) stock
Close on Nov 11, 2026Market cap $12.83MP/E –Yield –
PAVmed Inc. saw revenue fall 89.0% to $112.00K over the twelve months to Jun 30, 2026. Free cash flow was -$7.78M. At the latest close the market valued the company at $12.83M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $12.83M
- P/E ratio
- –
- Price to sales
- 114.58
- Price to book
- 0.37
- Dividend yield
- –
- Free cash flow yield
- -60.64%
Fundamentals
- Revenue
- $112.00K
- Net income
- -$12.09M
- EPS, diluted
- -$5.63
- Free cash flow
- -$7.78M
- Book value per share
- $5.59
- Diluted shares
- 6M
Trading
- Next earnings
- Nov 12, 2026 (estimated, before the open)
- Previous close
- $1.56
- Open
- $1.51
- Day's range
- $1.17 – $1.67
- Volume
- 18,933
- Average volume (20 days)
- 13,375
- Beta (5 years)
- 1.70
- 52-week range
- $1.17 – $28.44
- RSI (14 days)
- 26.1
- Volatility (1 year)
- 134.3%
- Relative volume
- 0.76×
- WACC
- 13.4%
Market cap history
Month-end market cap since 2016, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | PAVM | S&P 500 | Difference | PAVM per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -42.5% | -2.4% | −40.1 pts | ||
| 3 months | -65.9% | -1.2% | −64.8 pts | ||
| Year to date | -75.8% | +12.3% | −88.1 pts | ||
| 1 year | -84.7% | +12.4% | −97.2 pts | ||
| 3 years | -98.5% | +78.8% | −177.3 pts | -75.3% | +21.4% |
| 5 years | -99.9% | +75.2% | −175.1 pts | -76.6% | +11.9% |
| 10 years | -100.0% | +311.1% | −411.1 pts | -55.3% | +15.2% |
Twelve years at a glance
Fiscal years 2014 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases PAVmed filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Update
- Update
- Results
About PAVmed
Surgical & Medical Instruments & Apparatus
PAVmed Inc. is a diversified commercial-stage life sciences company operating across medical devices, diagnostics, and digital health through a shared services structure. Its diagnostics subsidiary, Lucid Diagnostics, provides the EsoCheck cell collection device and EsoGuard DNA test to detect esophageal precancer in at-risk patients with gastroesophageal reflux disease. Its digital health unit, Veris Health, delivers the Veris Cancer Care Platform and VerisBox connected devices for continuous physiological monitoring and remote symptom reporting during cancer treatment. In addition, the company develops medical devices, including the PortIO implantable intraosseous vascular access device and licensed endoscopic imaging technology. Customers and distribution channels include gastrointestinal specialists, primary care doctors, health systems, self-insured employers, unions, and cancer centers.
Company profile, executives and historyPAVmed stock: common questions
What is PAVmed's stock price?
PAVM closed at $1.60 on Nov 11, 2026, up 2.88% on the day. Over the past 52 weeks it traded between $1.17 and $28.44.
What is PAVmed's market cap?
PAVmed was worth $12.83M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is PAVM's P/E ratio?
PAVmed lost money over fiscal 2025 (diluted EPS -$5.63), so it has no meaningful P/E ratio.
How much revenue does PAVmed make?
PAVmed reported revenue of $112.00K for the twelve months to Jun 30, 2026, down 89.0% from a year earlier.
Does PAVmed pay a dividend?
No. PAVmed has not paid a cash dividend over the last twelve months.
When does PAVmed report earnings next?
PAVmed is expected to report Q3 FY2026 results on Nov 12, 2026, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has PAVM stock performed over the past year?
Including dividends, PAVM returned -84.7% over the past year, against +12.4% for the S&P 500.
How many PAVM shares are sold short?
0M shares were sold short at the latest FINRA report, 0.21% of the float, or 1.0 days of average trading volume.
Who are PAVmed's competitors?
Companies most similar to PAVmed by business, industry and size include GUTS, RDGL, PFSA, LUCD, QTEX.
See a number that looks wrong?